Bruce L. Levine
Impact in
- Oncology top 0.01%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 0.02%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
Papers in
- Oncology 187
- CAR-T cell therapy research 178
- Immunology 122
- Immune Cell Function and Interaction 71
- Immunotherapy and Immune Responses 57
- T-cell and B-cell Immunology 49
- Co-authors
- Carl H. June (154 shared papers)David L. Porter (26 shared papers)Michael D. Kalos (19 shared papers)Adam Bagg (4 shared papers)Stephan A. Grupp (32 shared papers)Anne Chew (22 shared papers)Jan Joseph Melenhorst (35 shared papers)Simon Francis Lacey (36 shared papers)
- Journals
- Blood (77 papers)Cytotherapy (30 papers)Clinical Cancer Research (9 papers)Transplantation and Cellular Therapy (9 papers)Science Translational Medicine (8 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Bruce L. Levine
303 papers receiving 54.4k citations
Bruce L. Levine's Hit Papers
Peers
Comparison fields: 5 of 181
- Oncology 39.1k
- Immunology 20.0k
- Genetics 11.5k
- Hematology 4.3k
- Virology 1.5k
Countries citing papers authored by Bruce L. Levine
This map shows the geographic impact of Bruce L. Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce L. Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce L. Levine more than expected).
Fields of papers citing papers by Bruce L. Levine
This network shows the impact of papers produced by Bruce L. Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce L. Levine. The network helps show where Bruce L. Levine may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce L. Levine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 309 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia Hit paper breakdown → | 2014 | 4551 |
| 2 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Hit paper breakdown → | 2018 | 4460 |
| 3 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia Hit paper breakdown → | 2011 | 3013 |
| 4 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Hit paper breakdown → | 2013 | 2979 |
| 5 | T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia Hit paper breakdown → | 2011 | 2026 |
| 6 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas Hit paper breakdown → | 2017 | 1531 |
| 7 | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma Hit paper breakdown → | 2017 | 1525 |
| 8 | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia Hit paper breakdown → | 2015 | 1482 |
| 9 | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia Hit paper breakdown → | 2018 | 1417 |
| 10 | CRISPR-engineered T cells in patients with refractory cancer Hit paper breakdown → | 2020 | 1170 |
| 11 | Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV Hit paper breakdown → | 2014 | 1105 |
| 12 | Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Hit paper breakdown → | 2013 | 978 |
| 13 | Characterization of the LIGO detectors during their sixth science run Hit paper breakdown → | 2015 | 968 |
| 14 | Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia Hit paper breakdown → | 2016 | 941 |
| 15 | Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Hit paper breakdown → | 2010 | 893 |
| 16 | Engineered T cells: the promise and challenges of cancer immunotherapy Hit paper breakdown → | 2016 | 885 |
| 17 | Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies Hit paper breakdown → | 2013 | 769 |
| 18 | Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Hit paper breakdown → | 2018 | 736 |
| 19 | NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Hit paper breakdown → | 2015 | 725 |
| 20 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells Hit paper breakdown → | 2022 | 711 |
About Bruce L. Levine
Bruce L. Levine is a scholar working on Oncology, Immunology, Hematology, Genetics and Virology, having authored 309 papers that have together received 56.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (178 papers), Immune Cell Function and Interaction (71 papers), Immunotherapy and Immune Responses (57 papers), T-cell and B-cell Immunology (49 papers), Virus-based gene therapy research (44 papers), Viral Infectious Diseases and Gene Expression in Insects (28 papers), CRISPR and Genetic Engineering (27 papers) and Hematopoietic Stem Cell Transplantation (25 papers). The work is most often cited by research in Oncology (39.1k citations), Immunology (20.0k citations), Genetics (11.5k citations), Hematology (4.3k citations) and Virology (1.5k citations). Bruce L. Levine has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Carl H. June, David L. Porter, Michael D. Kalos, Adam Bagg, Stephan A. Grupp, Anne Chew, Jan Joseph Melenhorst, Simon Francis Lacey, David T. Teachey and David Maxwell Barrett. Their work appears in journals such as Blood, Cytotherapy, Clinical Cancer Research, Transplantation and Cellular Therapy and Science Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.